NCT01369277 - A Single Dose Study In Japanese And Western Healthy Subjects To Investigate The Safety, Tolerability And Pharmacokinetics Of PF-04991532 | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

June 30, 2011

Primary Completion Date

September 30, 2011

Study Completion Date

September 30, 2011

Conditions

Diabetes MellitusDiabetes Mellitus, Type 2Glucose Metabolism Disorders

Interventions

DRUG

PF-04991532

Single dose administration of PF-04991532 (100 mg, 300 mg and 750 mg) in tablet formulation under fasted condition.

DRUG

Placebo

Single dose administration of matching placebo in tablet formulation at the fasted state

DRUG

PF-04991532

Single dose administration of PF-04991532 (300 mg and 750 mg) in tablet formulation under fasted condition.

Trial Locations (1)

Pfizer Investigational Site, New Haven